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Abstract
The exact mechanism underlying amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) associated with 
the GGG GCC repeat expansion in C9orf72 is still unclear. Two gain-of-function mechanisms are possible: repeat RNA 
toxicity and dipeptide repeat protein (DPR) toxicity. We here dissected both possibilities using a zebrafish model for ALS. 
Expression of two DPRs, glycine–arginine and proline–arginine, induced a motor axonopathy. Similarly, expanded sense 
and antisense repeat RNA also induced a motor axonopathy and formed mainly cytoplasmic RNA foci. However, DPRs 
were not detected in these conditions. Moreover, stop codon-interrupted repeat RNA still induced a motor axonopathy and a 
synergistic role of low levels of DPRs was excluded. Altogether, these results show that repeat RNA toxicity is independent 
of DPR formation. This RNA toxicity, but not the DPR toxicity, was attenuated by the RNA-binding protein Pur-alpha and 
the autophagy-related protein p62. Our findings demonstrate that RNA toxicity, independent of DPR toxicity, can contribute 
to the pathogenesis of C9orf72-associated ALS/FTD.
Keywords ALS · C9orf72 · DPR · RNA toxicity · Pur-alpha · p62 · Zebrafish
Introduction
A GGG GCC hexanucleotide repeat in the 5′ end of the 
C9orf72 gene is the most frequent genetic cause of amyo-
trophic lateral sclerosis (ALS) and frontotemporal dementia 
(FTD) [16, 22, 38]. ALS is characterized by motor neuron 
degeneration in the spinal cord, brainstem and motor cortex, 
and presents with progressive muscle weakness and wasting. 
It is rapidly progressive and usually fatal within 3–5 years 
after diagnosis. FTD presents with behavioral and/or lan-
guage abnormalities, caused by degeneration of neurons in 
the frontal and temporal cortex. ALS and FTD form a con-
tinuum and are thought to be different clinical expressions 
of one disease [39].
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The GGG GCC expansion in C9orf72 underlies ~ 40% of 
familial ALS and ~ 25% of familial FTD cases. It is also 
found in nearly 10 and 5% of patients with apparent non-
familial ALS or FTD, respectively [37]. Control individuals 
most often carry 2–8 repeats, whereas patients have hun-
dreds and even up to several thousands of repeats [46, 24]. 
At the cellular level, ALS/FTD associated with the C9orf72 
expansion mutation (here called C9 ALS/FTD) is character-
ised by nuclear, and to a lesser extent cytoplasmic, RNA foci 
that contain sense GGG GCC or antisense CCC CGG repeats 
[26]. Furthermore, repeat-associated non-ATG (RAN) trans-
lation products (called dipeptide repeat proteins or DPRs) 
have been identified in the p62-positive, TDP43-negative 
inclusions that are characteristically found in C9 ALS/FTD 
patients. RAN translation is an unusual type of translation 
that generates aggregation-prone repeats of dipeptides from 
all three reading frames from both sense and antisense repeat 
RNA [19, 26].
The exact pathogenic mechanism underlying C9 ALS/
FTD remains unknown. Because of reduced expression of 
C9orf72 transcripts in brain tissue and cells [3, 50], a loss-
of-function mechanism has been proposed. Knockdown of 
C9orf72 in zebrafish and C. elegans indeed resulted in a 
neuronal phenotype [8, 44]. However, several mouse models 
with a general or neuron-specific deletion of C9orf72 did 
not develop clinical or pathological signs of motor neuron 
disease [2, 27, 28, 35, 42]. Instead, some models developed 
splenomegaly, lymphadenopathy, auto-immune disorders 
and neoplastic events, indicative of a primary role of the 
C9orf72 protein in immunity [2, 35, 42]. Interestingly, the 
C9orf72 protein has been shown to be a key player in regu-
lation of autophagy [49]. Moreover, homozygosity for the 
repeat expansion does not generate a phenotype in humans 
that is worse than heterozygosity [18]. Altogether, the cur-
rent data make loss-of-function rather unlikely to be a causal 
mechanism, although it remains to be investigated how loss-
of-function mechanisms might contribute to the disease.
In contrast, mice overexpressing the hexanucleotide 
expansion developed a motor neuron syndrome accompanied 
by the same pathological hallmarks as observed in C9 ALS 
patients [7, 32]. Furthermore, treatment of iPSC-derived 
neurons (iPSNs) from C9 patients with C9 antisense oligo-
nucleotides at least partially corrected their phenotype, all 
suggesting a gain-of-function pathogenic mechanism [17, 
41].
Two such mechanisms have been proposed. First, a patho-
genic gain-of-function mechanism relates to the toxicity of 
DPRs generated through RAN translation, and will be called 
‘DPR toxicity’. The arginine-containing DPRs, PR (pro-
line–arginine) and GR (glycine–arginine), have been shown 
to be toxic in yeast and Drosophila, whereas PR, GR, as 
well as GA (glycine–alanine) and GP (glycine–proline) are 
able to induce toxicity in a variety of cells [19]. Moreover, 
overexpression of GA might induce neurodegeneration in 
mice [53]. However, on postmortem examination of C9orf72 
ALS patients, the pattern of DPR deposition poorly cor-
relates with the pathological hallmarks of ALS (especially 
TDP43 pathology and motor neuron predominance) or with 
several clinical parameters [19, 26].
Alternatively, the GGG GCC repeat RNA has been 
hypothesized to be toxic itself (‘RNA toxicity’). Several 
mechanisms underlying such toxicity are possible, one of 
them being sequestration of proteins essential for normal 
RNA processing, which leads to widespread errors in RNA 
metabolism and eventually to neuronal dysfunction. This is 
similar to what has been suggested to occur in other RNA 
repeat diseases such as myotonic dystrophy. In vivo and 
in vitro studies identified a list of RNA-binding proteins that 
bind to C9 repeats [26]. Indeed, C9 repeats have been shown 
to induce splicing dysregulation [10], especially by seques-
tration of hnRNPH [9]. Additionally, C9 repeats might inter-
fere with mRNA transport granules in vitro [6]. However, 
data supporting RNA toxicity in a vertebrate model are cur-
rently lacking.
While a gain-of-function mechanism seems to be evident, 
so far it is still unclear whether this relies on DPR toxicity 
or RNA toxicity, or a combination of both. Here, we dissect 
the two proposed gain-of-function mechanisms in an in vivo 
zebrafish model for C9 ALS. This model is similar to previ-
ously established ALS zebrafish models [29, 31] which have 
generated robust, relevant and translational insights into the 
pathogenesis of ALS [47].
Materials and methods
Plasmids and in vitro RNA transcription
Constructs containing 3, 4 or 10 GGG GCC repeats were 
synthesized (IDT, Leuven, Belgium), digested with EcoRI 
and subcloned into the pCMV6-Entry vector (Origene, 
Rockville, USA), containing a T7 promoter, to generate 
the p3-S, p4-S and p10-S plasmids. The p35-S and p35-AS 
plasmids, containing ~ 35 GGG GCC or ~ 35 CCC CGG 
repeats, were generated by EcoRI digestion of the pATG75 
construct [25] and ligation into the pCMV6-Entry vector. 
Plasmids pUAST91, containing 91 GGG GCC hexanucleo-
tide repeats, and pUAST108RO [33], containing 108 GGG 
GCC stop codon-interrupted repeats, were digested with 
EcoRI/NotI and KpnI, respectively, and the repeat was sub-
cloned into the pCMV6-Entry vector to generate the p90-S 
and the p108RO-S plasmids. In both plasmids, a reverse 
complementary sequence of the T3 promoter was inserted 
30 bp after the repeats to generate antisense transcripts. Dur-
ing propagation of these plasmids, shorter constructs con-
taining ~ 70 non-stop (70S) or 70 stop codon-interrupted 
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(70RO) repeats were obtained by spontaneous repeat dele-
tions. Direction of the inserted repeats was controlled by 
Sanger sequencing (LGC Genomics, Berlin, Germany) and 
repeat length was estimated by restriction analysis. All final 
constructs were transformed and propagated in an E. coli 
Stbl3 background (Life Technologies, Gent, Belgium) to 
minimize spontaneous contractions/expansions of the repeat.
The plasmids encoding the DPRs GA, GR, PR and PA, all 
containing 50 repeats and a C-terminal FLAG tag, as well as 
the Pur-alpha deletion constructs, all containing a C-terminal 
FLAG tag, were synthesized (Genscript, Piscataway, USA) 
and subcloned into the pCMV6-Entry vector. The construct 
containing 50 GP repeats was obtained through spontaneous 
contraction of a construct containing 100 GP repeats [kind 
gift from M. Yamakawa (Keio University School of Medi-
cine, Tokyo, Japan)] [52]. Sequences from all constructs can 
be provided upon request.
The human Pur-alpha FLAG-tagged encoding plasmid 
(RC206280) and the human p62 FLAG-tagged encoding 
plasmid (RC203214) were purchased from Origene.
To synthesize RNA, all plasmids were linearized by 
restriction digestion, transcribed with the mMESSAGE 
 mMACHINE®T7 or T3 kit (Ambion, Huntingdon, UK) 
and the resulting RNA purified with the MEGAclear™ Kit 
(Ambion). RNA concentration was determined by spectro-
photometry (Nanodrop, Thermo Fisher Scientific). RNA 
quality and length was verified by RNA gel electrophoresis.
Repeat RNA was fluorescently labeled with the Ulysis™ 
AlexaFluor™ 594 Nucleic Acid Labeling Kit (Thermo 
Fisher Scientific) according to the manufacturer’s instruc-
tions and subsequently purified using Micro Bio-Spin® 
Columns with Bio-Gel® P-30 (Bio-Rad) according to the 
manufacturer’s instructions.
ATG blocking morpholinos against Danio rerio sqstm1 
(transcript NM_001312913.1; morpholino sequence 5′-AGC 
TTT CAC TGT CAT CGA CAT CGT A-3′) and Danio rerio pur-
alpha (transcript NM_001001846.1; morpholino sequence 
5′-CCA CTG TCT CTG TCC GCC ATG ATG C-3′) were 
designed and generated by Gene Tools (Philomath, USA). 
The standard control oligo provided by Gene Tools was used 
as negative control.
Zebrafish injections, SV2 immunohistochemistry 
(IHC) and phenotyping
Zebrafish work was performed as previously described [31]. 
One- to two-cell stage zebrafish embryos from the AB strain 
were injected in the yolk sac with the indicated amounts of 
the different RNAs. Injected embryos were kept in a 28 °C 
incubator. After 24-h post-fertilization (hpf) the embryos 
were manually dechlorinated using a forceps. Subsequently, 
the embryos underwent a rigorous visual inspection for dys-
morphic features. Only morphologically normal embryos 
were retained. At 30 hpf, the morphologically normal fish 
were manually deyolked and subsequently fixed overnight 
at 4 °C in 4% formaldehyde in phosphate-buffered saline 
(PBS). Fish were permeabilized with acetone for 1 h at 
− 20 °C, blocked with 1% BSA/1% DMSO/PBS for 1 h at 
room temperature and immunostained with mouse anti-SV2 
(1/200; AB2315387 (http ://anti body regi stry .org), Develop-
mental Studies Hybridoma Bank, University of Iowa, Iowa 
City, USA) and secondary Alexa Fluor 555 anti-mouse anti-
body (1/500; Molecular Probes, Eugene, USA).
For phenotyping, 15 consecutive embryos per condition 
were analyzed with imaging (Leica DM 3000 LED micro-
scope; DMK 33UX250 USB3.0 monochrome industrial 
camera, The Imaging Source, Bremen, Germany) using 
Lucia software (version 4.60, Laboratory Imaging, Prague, 
Czech Republic) by a blinded observer. For the axonal 
length, a standardized method was used; five predefined and 
consecutive motor axons (i.e., the 8th up to the 12th axon 
on one side) were measured in all 15 embryos. Data for 
axonal length were normalized to the control condition. For 
the abnormal branching, a predefined set of 20 consecutive 
motor axons (i.e., the 8th up to the 17th axon on both sides) 
in these same 15 embryos was analyzed visually. Motor 
axons were considered abnormal when axons branched at 
or before the ventral edge of the notochord. An embryo was 
considered as having ‘abnormal branching’ when at least 
two of these 20 axons were abnormal.
Number of biological replicates (‘n’) is indicated in each 
figure legend. Number of biological replicates equals at least 
three, which has been shown previously to be adequate to 
measure an effect [31]. For each experiment, GFP-encoding 
RNA was used as control at the same amount as the highest 
dose of the tested RNA.
Dot blot
Fish were homogenized in RIPA buffer supplemented 
with protease inhibitors (Complete, Roche) using sonica-
tion (Branson, model 102C) at 30 hpf. After centrifugation 
(10 min, 12,000 rpm) supernatant was collected and heated 
at 95 °C for 5 min. One to ten microliters of this supernatant 
was applied on a nitrocellulose membrane with pore size 
0.2 µm (Amersham, GE Healthcare Life Sciences) and air-
dried for 25 min. After overnight blocking in 5% non-fat dry 
milk in Tris-buffered saline (TBST; 10 mM Tris, 150 mM 
NaCl, pH 7.6) at 4 °C, membranes were incubated with the 
appropriate primary antibodies (rabbit anti-PR and rabbit 
anti-GP were obtained from Thermo Scientific (custom-
made), rabbit anti-GR (23978-1-AP, validation data reported 
on the manufacturer’s website) antibody was obtained from 
Proteintech (Manchester, UK) at a dilution of 1/1000 in 
TBST for 2 h at room temperature. After three-time 15-min 
washing with TBST, blots were incubated with secondary 
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antibody (polyclonal goat anti-rabbit-immunoglobulins/
HRP, DAKO, 1/5000 in TBST) at room temperature. After 
two-time 15-min washing with TBST and one wash with 
TBS, blots were visualized by chemiluminescence (ECL 
Western Blotting Substrate or SuperSignal West Femto 
Maximum Sensitivity Substrate, Thermo Fisher Scientific; 
ImageQuant Las 4000, GE Healthcare Life Sciences).
Western blot
Fish samples were homogenized in RIPA buffer supple-
mented with protease inhibitors using sonication. After 
protein quantification (Micro BCA™ Protein Assay Kit 
#23235, Thermo Fisher Scientific, Waltham, USA) appro-
priate amounts of sample were resolved on 12% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to a polyvinyldifluoride membrane 
 (Immobilon®-P, Merck Millipore, Billerica, USA) using a 
semi-dry blotting apparatus (TE70XP, Hoefer, San Fran-
cisco, USA). After blocking with 5% non-fat dry milk in 
TBST for 1 h at room temperature, the membranes were 
incubated overnight at 4  °C with the primary antibody 
(mouse anti-FLAG antibody, Sigma #F1804 (http ://anti 
body regi stry .com AB_262044), 1/500; rabbit anti-p62, 
MBL International #PM045, 1/1000; mouse anti-beta-actin, 
Sigma #A5441 (http ://anti body regi stry .com AB_476744), 
1/1000; rabbit anti-Pur-alpha, Abcam #ab79936, 1/500) in 
TBST, washed three times with TBST and incubated with 
secondary antibody (polyclonal goat anti-rabbit/mouse-
immunoglobulins/HRP, DAKO, 1/5000 in TBST) during 
1 h. After two-time 15-min washing with TBST and one 
wash with TBS, blots were visualized by chemiluminescence 
(cf. supra).
GP immunoassay
Fish were homogenized in RIPA buffer supplemented with 
protease inhibitors using sonication. Levels of soluble 
poly(GP) were measured using a previously described sand-
wich immunoassay using a poly(GP) antibody [21].
qPCR
Total RNA was extracted with Trizol (Thermo Fisher Scien-
tific, Waltham, USA) and precipitated with isopropyl alco-
hol according to the manufacturer’s instructions. cDNA was 
synthesized from 1 μg of total RNA with SuperScript III 
Reverse transcriptase (Thermo) and random hexamer prim-
ers, according to the manufacturer’s instructions. Quantita-
tive PCR was performed using StepOnePlus™ (Life Tech-
nologies) with  TaqMan® Fast Universal PCR Master Mix 
(Life Technologies). Gene expression assays were purchased 
from Life Technologies: Danio rerio p62, Dr03114502_m1; 
Danio rerio Acta 1b, Dr03440340_m1. Relative gene 
expression was determined by the  2−ΔΔct method and nor-
malized to the average of the control group. Graphs repre-
sent gene expression relative to Acta1b expression.
RNA pull‑down assay
Biotinylated RNAs used were generated by in vitro bioti-
nylation (Pierce RNA 3′ END Biotinylation Kit, Thermo 
Scientific), according to the manufacturer’s instructions, 
from different constructs, indicated where appropriate. Adult 
mouse brain was homogenized in T-PER buffer (Thermo 
Fisher Scientific) supplemented with protease inhibitors by 
mechanical disruption for 30 s (MagNA Lyser, Roche). HEK 
cells were transiently transfected with the different Pur-alpha 
constructs using Lipofectamine 2000 (Invitrogen), according 
to the manufacturer’s instructions, lysed 48 h post-transfec-
tion with T-PER buffer and analyzed for protein concentra-
tion. Lysates were precleared by incubation with magnetic 
streptavidin-coated beads (Life Technologies) for 1 h at 4 °C. 
Ten picomoles of biotinylated repeat RNA were denatured 
at 95 °C for 10 min and incubated overnight at 4 °C with 
1 mg of lysate. RNA and bound proteins were pulled down 
with 40 µl of magnetic streptavidin-coated beads for 1 h at 
4 °C. Samples were washed five times in ice-cold PBS and 
denatured in SDS containing loading buffer and separated 
by SDS-PAGE followed by Western blotting.
Whole‑mount zebrafish immunohistochemistry
Whole-mount zebrafish staining of embryos injected with 
fluorescently labeled repeat RNA or codon-optimized DPR 
constructs was similar to SV2 staining (cf. supra). Anti-
bodies used were anti-FLAG (Sigma #F1804, 1/250), anti-
eif3e (Abcam #ab36766, 1/250) and anti-Pur-alpha (Abcam 
#ab79936, 1/250). Subsequently, nuclei were visualized 
using NucBlue counterstaining (Thermo Fisher Scientific). 
Embryos were mounted using ProLong Gold antifade rea-
gent (Life Technologies). Images were taken using Leica 
TCS SP8 confocal microscope equipped with Leica HyD™ 
detector and Leica Las X (version 3.1.1.15751) software. 
Quantification of RNA foci was performed using ImageJ 
software.
Statistical analysis
Statistics were performed using GraphPad Prism software 
(GraphPad Software, San Diego, USA) or RStudio [RStu-
dio Team (2015). RStudio: Integrated Development for R. 
RStudio, Inc., Boston, MA URL (http ://www.rstu dio.com/)]. 
For zebrafish experiments axonal length was analyzed with 
one-way ANOVA (GraphPad Prism), Shapiro–Wilk normal-
ity test (GraphPad Prism) was used to check for normality. 
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For multiple comparisons, Tukey’s post hoc correction was 
applied. Axonal length is represented as bar graphs with 
indication of mean and 95% confidence interval. Abnormal 
branching was pooled and analyzed using logistic regres-
sion (RStudio) and represented as a pooled proportion, with 
indication of 95% confidence interval. Protein expression 
assessed by Western blot was analyzed by two-tailed ratio 
paired t test (GraphPad Prism), Shapiro–Wilk normality 
test (GraphPad Prism) was used to check for normality, and 
represented as dot plots with indication of mean ± SEM. 
RNA levels assessed by qPCR were analyzed with one-way 
ANOVA (GraphPad Prism), Shapiro–Wilk normality test 
(GraphPad Prism) was used to check for normality, and rep-
resented as dot plots with indication of mean ± SEM. Sig-
nificance level was defined at 0.05. Significance levels are 
indicated in the figures as follows: * p < 0.05, ** p < 0.01, 
*** p < 0.001, **** p < 0.0001.
Results
Sense and antisense RNA repeats induce motor 
axon abnormalities in zebrafish
We first investigated whether GGG GCC repeat RNA was 
toxic to zebrafish motor axons. We injected RNA consisting 
of ~ 70 GGG GCC repeats in zebrafish embryos and com-
pared motor axonal outgrowth to the control condition by 
injecting 3 GGG GCC repeat RNA. RNA of ~ 70 GGG GCC 
repeats dose dependently induced a motor axonopathy con-
sisting of reduced axonal outgrowth and aberrant branching 
at 30 hpf (Fig. 1a–d). These abnormalities were very similar 
to those described for mutant SOD1 and TDP43 [29, 31], 
two other genetic causes of ALS. Next, we injected RNA 
consisting of 3, 4, 10, ~ 35, ~ 70 and ~ 90 GGG GCC repeats, 
in equimolar concentration to the highest dose (0.844 µM) 
used in Fig. 1c, d to determine a repeat length-dependent 
effect. Ten or less repeats did not affect axon morphology 
(Fig. 1e, f). From ~ 35 repeats on, a clear axonopathy was 
induced, which did not increase in severity with repeat 
length (Fig. 1e, f).
Because the expanded repeat in patients is also tran-
scribed in the antisense direction, we next studied the effect 
of expanded antisense repeats, in particular ~ 35 and ~ 70 
CCC CGG repeats. Interestingly, injection of RNA consist-
ing of ~ 70 antisense repeat RNA (0.844 µM) also induced 
a  motor axonopathy in zebrafish (Fig.  1g, h). Of note, 
the ~ 35 antisense repeat RNA was less toxic to the fish 
(Fig. 1g, h) than the ~ 70 antisense repeat RNA (no effect 
on axonal length and a more limited effect on branching) 
indicating a higher threshold for toxicity compared to sense 
repeats.
These data implicate that both sense and antisense 
C9orf72 hexanucleotide repeat RNA induced motor neuron 
toxicity when injected into zebrafish embryos. Moreover, 
this toxicity displayed a length-dependent threshold effect 
and the antisense repeats were less toxic than the sense 
repeats.
Next, we investigated the cellular distribution of repeat 
RNA by injecting fluorescently labeled 3 sense, ~ 90 sense 
and ~ 70 antisense repeat RNA. All three RNAs were found 
to be diffusely present in the cytoplasm, and mainly in neu-
ral tissue (Online Resource 1a–h). In addition, they clearly 
formed cytoplasmic RNA foci (Fig. 1i–k), both in neural and 
non-neural tissue. Of note, these RNA foci did not colocalize 
with stress granules (Online Resource 1i–l).
Arginine‑containing RAN translation products 
induce motor axon abnormalities in zebrafish
To determine whether RAN translation products mediate 
the toxicity of sense and antisense repeat RNA, we first 
investigated whether DPR proteins themselves are toxic to 
motor axons in the fish. To this end, DPR expression con-
structs were designed that generate the five possible DPRs 
observed in C9 ALS/FTD, i.e., GA, GR, GP, PR and PA 
(proline–alanine), all with a length of 50 repeats. These 
constructs contained an ATG start codon and were codon 
optimized [4]. This was obtained by choosing codons so that 
they encode the correct amino acid, but without repeats in 
the RNA, thus avoiding the potential toxicity of the repeat 
RNA. The expression of four DPRs (GR, PR, GA and GP), 
but not PA, was detectable in zebrafish using Western blot 
or dot blot (Fig. 2a).
Expression of GR and PR in zebrafish induced dose-
dependent toxicity (Fig. 2b, c and Online Resource 2). In 
contrast, expression of GP, GA or PA did not result in any 
motor axon abnormalities (Fig. 2b, c and Online Resource 
2).
As an additional control to exclude an RNA-mediated 
contribution to the phenotype observed, we deleted the ATG 
start codon in the PR construct to abolish PR production 
(Fig. 2a). Injection of this RNA in zebrafish embryos did 
not induce any abnormalities of axonal length or branching 
(Fig. 2d, e). Altogether, these data suggest that arginine-
containing DPRs (i.e., GR or PR) can induce motor neuron 
toxicity in the zebrafish model.
To investigate the cellular distribution of the DPRs in 
zebrafish embryos, we performed whole-mount staining 
using FLAG antibody. GA formed abundant cytoplasmic 
aggregates in varying locations in the embryo, both in neu-
ral and non-neural tissue (Fig. 2f–h). GR, GP, PR and PA 
did not form detectable aggregates on whole-mount staining 
(data not shown).
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Repeat RNA toxicity is independent of DPR toxicity
To investigate whether the effects caused by the expanded 
sense and antisense repeats (Fig. 1) were a direct effect of 
RNA toxicity or whether they were (at least partially) medi-
ated by DPR production through RAN translation, we next 
investigated the expression of DPRs in the injected fish.
First, we assessed whether PR, which is the only toxic 
DPR in our model that was generated from the antisense 
strand, was present in fish injected with antisense repeat 
RNA. Using an anti-PR dot blot assay, PR was not detectable 
in fish injected with the clearly toxic dose of ~ 70 antisense 
RNA (0.844 µM), while it was readily detectable in fish 
injected with decreasing doses of PR RNA (Fig. 3a–c). Inter-
estingly, although in low amounts, PR was even detectable in 
non-toxic PR conditions (0.211 and 0.106 µM) (Fig. 3a–c). 
Combined, these data indicate that toxicity in our ~ 70 anti-
sense RNA model is unlikely to be caused by PR generated 
through RAN translation.
Second, we investigated whether GR, the only toxic 
DPR generated from the sense strand in our model, is 
formed in fish injected with sense repeat RNA. Using an 
anti-GR dot blot assay, GR was not detected in any of 
the sense RNA conditions, while it was readily detectable 
Fig. 1  Zebrafish axonopathy induced by C9orf72 sense and anti-
sense repeats. a, b Visualization of motor axons by immunohisto-
chemistry (SV2 antibody) of 30 hpf zebrafish embryos injected with 
3S (a) or  ~  70S (b) repeat RNA. c, d Axonal length (c) and aber-
rant axonal branching (d) of zebrafish embryos injected with increas-
ing doses of 3 and ~ 70 sense repeat RNA, compared to GFP control 
RNA, n = 5 experiments. c Data represent mean ± 95% confidence 
interval (CI) one-way ANOVA, F(6, 754) = 18.87, ****p < 0.0001. 
d Data represent mean ± 95% CI logistic regression (z values com-
pared to GFP −  0.796, −  0.877, −  0.200, 3.025, 0.104, 5.703; z 
values for 3S vs 70S: 1.373, 2.480, 4.538), *p < 0.05, **p < 0.01, 
***p  <  0.001. e, f Axonal length (e) and aberrant axonal branch-
ing (f) of zebrafish embryos injected with sense repeat RNA with a 
length of 3 (n  =  4 experiments), 4 (n  =  4 experiments), 10 (n  =  4 
experiments),  ~  35 (n  =  4 experiments),  ~  70 (n  =  24 experi-
ments) and  ~  90 (n  =  4 experiments) repeats at equimolar dose 
(0.844 µM). e Data represent mean ± 95% CI one-way ANOVA, F(6, 
1140)  =  57.16, ****p  <  0.0001. f Data represent mean  ±  95% CI 
logistic regression (z values compared to GFP 1.130, − 0.573, 1.130, 
3.035, 3.063, 2.565), *p < 0.05, **p < 0.01. g, h Axonal length (g) 
and axonal branching (h) of zebrafish embryos injected with anti-
sense repeat RNA with a length of ~ 35 (n = 4 experiments) and ~ 70 
(n = 12 experiments) repeats at equimolar dose (0.844 µM). g Data 
represent mean  ±  95% CI one-way ANOVA, F(2, 474)  =  35.66, 
****p < 0.0001. h Data represent mean ± 95% CI logistic regression 
(z values compared to GFP 2.450, 3.576), *p < 0.05, **p < 0.01. i–k 
Whole-mount staining (SV2 antibody) of 30  hpf zebrafish embryos 
injected with fluorescently labeled 3S, ~ 90S and ~ 70AS repeat RNA
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in fish injected with RNA encoding GR protein (Fig. 3c). 
This suggests that sense toxicity in this model is unlikely 
to be caused by GR generated through RAN translation.
Third, we assessed the presence of GP, a DPR gener-
ated from the sense and/or antisense strand, which is not 
toxic in our model. GP was not detected, by dot blot assay, 
in any of the sense or antisense conditions, while it was 
detected in fish injected with GP RNA (Fig. 3c). GP was 
detected by immunoassay in fish injected with the toxic 
sense repeat RNA, but only at very low levels (marginally 
above the limit of detection) compared to fish injected with 
GP RNA (Fig. 3d).
We next excluded the contribution of low levels of DPRs 
acting synergistically with the toxicity induced by repeat 
RNA. This is of interest since in C9 patients more than one 
DPR may co-exist in the same cell. To investigate this, we 
first co-expressed low levels (0.211 µM, Online Resource 2) 
of all four DPRs of which the expression could be demon-
strated using dot blot or Western blot (Fig. 2a). Coexpression 
of these DPRs did not result in synergistic toxicity of these 
Fig. 2  DPR-induced axonopathy in zebrafish. a Western blot using 
anti-FLAG antibody to detect formation of GA in fish injected with 
GA-coding mRNA (upper panel) and dot blots using DPR-specific 
antibodies to detect PR, GR and GP, respectively (three lower pan-
els; pictures for GR and GP are derived from the dot blots in Fig. 3c), 
n = 3 biological replicates. b, c Quantification of axonal length (b) 
and aberrant axonal branching (c) of fish injected with equimolar 
amounts (0.844  µM) of codon-optimized RNA encoding a single 
DPR, compared to GFP control RNA (n = 18 experiments). b Data 
represent mean  ±  95% CI one-way ANOVA, F(5, 1390)  =  55.07, 
****p < 0.0001. c Data represent mean ± 95% CI logistic regression 
(z values compared to GFP 1.693, 7.090, − 0.177, 7.410, − 0.533), 
***p < 0.001. d, e Quantification of axonal length (d) and aberrant 
axonal branching (e) of fish injected with increasing doses of PR-
encoding RNA with a mutation of the ATG start codon (‘PRmut’), 
n  =  3 experiments. d Data represent mean  ±  95% CI one-way 
ANOVA, F(3, 179) = 0.3464. e Data represent mean ± 95% CI logis-
tic regression (z values compared to GFP 0.828, 0.558, 0.854). f–h 
Whole-mount staining (FLAG antibody) of 30 hpf zebrafish embryos 
injected with GA-coding mRNA
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DPRs (Fig. 4a, b). Second, since DPRs also co-exist with 
repeat RNA in cells of C9 patients, we also co-injected the 
combination of DPRs with low non-toxic levels (0.211 µM, 
Fig. 1c, d) of ~ 70 sense repeat RNA. Again, no increase in 
toxicity was noted (Fig. 4a, b). Third, low non-toxic levels 
(0.211 µM) of ~ 90 sense or ~ 70 antisense repeat RNA 
were co-injected with high non-toxic levels (0.844 µM) of 
GA- or GP-coding RNA. Again, neither GA nor GP were 
found to act synergistically with sense (Fig. 4c, d) or anti-
sense (Fig. 4e, f) repeat RNA. Altogether, these data suggest 
that the toxicity of repeat RNA is not mediated through a 
synergistic effect with several DPRs, further supporting the 
existence of RNA toxicity.
Finally, we studied the effect of stop codon-interrupted 
repeat RNA, designated ‘RNA only’ (RO) repeat RNA. It 
has previously been shown that these constructs are not 
RAN translated and do not generate DPRs, while they still 
adopt the same stable conformation as the uninterrupted 
GGG GCC repeat RNA [33]. Interestingly, in spite of not 
being able to generate DPRs, sense RO repeat RNA (70RO 
and 108RO) still significantly affected axonal length and 
axonal branching, although to a somewhat lesser degree 
than the uninterrupted repeat RNA (Fig. 4g, h). Similarly, 
antisense RO repeat RNA (70RO AS and 108RO AS) was 
still toxic to the fish but to a lesser extent than uninter-
rupted repeat RNA (Fig. 4g, h). Thus, the presence of 
stretches of either sense or antisense C9orf72 hexanucleo-
tide repeat RNA in the complete absence of any DPRs was 
sufficient to cause motor neuron toxicity in our zebrafish 
model, supporting the existence of RNA toxicity.
Altogether, our results indicate that expanded sense and 
antisense repeats are directly toxic to motor axons, inde-
pendent of the formation of DPRs.
Fig. 3  DPRs are not detected in C9orf72 repeat RNA injected 
zebrafish. a, b Axonal toxicity of decreasing concentrations of PR-
encoding mRNA and ~ 70AS (0.844 µM), statistics are compared to 
GFP condition (n = 6 experiments). a Data represent mean ± 95% CI 
one-way ANOVA, F(6,1009) = 21.09, ****p < 0.0001. b Data repre-
sent mean ± 95% CI logistic regression (z values compared to GFP; 
4.554, 2.750, − 0.013, − 0.013, 4.900), **p < 0.01, ****p < 0.0001. 
c Dot blots of zebrafish samples (n  =  3 biological replicates) at 
30 hpf, all injected with equimolar amounts (0.844 µM) of indicated 
RNA. The upper panel represents a dot blot stained with anti-PR anti-
body of zebrafish samples of the same conditions as (a) and (b). The 
lower two panels represent dot blots, stained with GR- and GP-anti-
body, respectively. d Immunoassay using GP-antibody of zebrafish at 
30  hpf (n  =  3), all injected with equimolar amounts (0.844  µM) of 
indicated RNA (NI non-injected embryos)
435Acta Neuropathologica (2018) 135:427–443 
1 3
RNA‑binding protein Pur‑alpha prevents 
the axonopathy induced by sense and antisense 
repeat RNAs
In patients, RNA toxicity of C9orf72 hexanucleotide repeat 
expansions has been hypothesized to be due to the seques-
tration of several RNA-binding proteins [23]. Therefore, 
we investigated whether different RNA-binding proteins 
known to bind GGG GCC repeats, such as Pur-alpha [12, 
41, 51], hnRNPH1 [30] and hnRNPA1 [41], are also able 
to bind the toxic RNA repeats used in our model. Pur-alpha 
indeed bound to the toxic sense (~ 70S, 108RO) repeat RNA 
and, albeit with less affinity, to the toxic antisense (~ 70AS, 
108RO AS) repeat RNA (Online Resource 3a). Moreover, 
hnRNPA1 and hnRNPH1 also bound the ~ 70S repeat RNA 
(Online Resource 3a).
Next, we studied the effect of these RNA-binding proteins 
on the axonal phenotype induced by toxic repeat RNA in the 
zebrafish. Expression of Pur-alpha dose dependently pre-
vented the axonal abnormalities induced by the ~ 70 sense 
repeat RNA (Fig. 5a, b). In contrast, expression of hnRNPA1 
and hnRNPH1 at its highest non-lethal concentration had 
no effect on the toxic effect of sense repeat RNA (Fig. 5c, 
d), indicating that the protective effect of Pur-alpha was 
specific, rather than a general effect of any RNA-binding 
protein. Interestingly, overexpression of Pur-alpha induced 
a 50% decrease in ~ 90 sense RNA foci (Fig. 5e–g), whereas 
Pur-alpha was only occasionally found to colocalize with 
3 sense, ~ 90 sense and ~ 70 antisense RNA foci (Online 
Resource 3g–j). Of note, Pur-alpha also prevented the tox-
icity induced by the ~ 70 antisense repeat RNA (Online 
Resource 3b, c) and the 108RO sense repeat RNA (Online 
Resource 3d, e), which is DPR independent.
Finally, we tested the effect of Pur-alpha on DPR toxicity. 
Despite being able to bind the RNA encoding GR (Online 
Resource 3f), Pur-alpha overexpression did not prevent the 
axonopathy induced by it, nor by the RNA encoding PR 
(Fig. 5h, i). Thus, in our model Pur-alpha prevents repeat 
RNA toxicity but does not modify DPR toxicity. This dif-
ferential effect of Pur-alpha again underscores the conclu-
sion that a different pathophysiological mechanism underlies 
these two forms of toxicity.
The protective effect of Pur‑alpha is mediated by its 
G‑rich and PUR2 domain
To further explore the protective role of Pur-alpha, we gener-
ated and expressed five different Pur-alpha constructs in the 
zebrafish, each lacking one of the five functional domains 
[14] (Fig. 6a, b) and tested their ability to prevent the toxic-
ity induced by toxic sense repeat RNA.
First, the binding affinity of these recombinant Pur-alpha 
proteins to sense repeat RNA was assessed by RNA pull-down 
using biotinylated ~ 90 sense repeat RNA. Interestingly, all 
Pur-alpha deletion proteins were still able to bind sense repeat 
RNA to a similar extent as the wild-type Pur-alpha protein 
(Fig. 6c, d).
Next, we co-injected toxic sense RNA either with RNA 
encoding GFP (control), wild-type Pur-alpha or one of the five 
Pur-alpha deletion proteins. We found that the G-rich domain 
and the PUR2 domain, but not the PUR1, the PUR3 or the 
EQ domains, are necessary for Pur-alpha to have its effect on 
repeat RNA-induced toxicity, as their deletion abolished the 
protective effect (Fig. 6e, f). As the binding of the ΔG and 
ΔPUR2 proteins to the ~ 90 sense RNA is not altered, these 
data suggest that the G-rich domain and the PUR2 domain 
mediate a downstream effect of the Pur-alpha protein which 
is responsible for the protection against repeat RNA toxicity.
p62 is upregulated by Pur‑alpha and prevents 
repeat RNA toxicity
As p62 protein levels have previously been shown to be 
increased in C9orf72 iPSC-derived neurons [1, 13], we 
investigated the possible involvement of p62 in our zebrafish 
model. Injection of sense repeat RNA did not modify the 
protein (Fig. 7a, Online Resource 4a) and mRNA (Online 
Resource 4b) levels of p62. However, overexpression of Pur-
alpha increased protein levels of p62 without affecting the p62 
mRNA levels, while p62 protein levels were not increased 
upon overexpression of ΔG and ΔPUR2 (Fig. 7b, Online 
Resource 4c). Since ΔG and ΔPUR2 also failed to prevent 
RNA toxicity (Fig. 6e, f), this suggests that p62 induction is 
necessary for Pur-alpha to have its protective effect. Indeed, 
upon morpholino-mediated p62 knockdown (Online Resource 
4d, e), the protective effect of Pur-alpha was abolished (Fig. 7c, 
d). Interestingly, morpholino-mediated Pur-alpha knockdown 
resulted in a decrease in p62 levels (Fig. 7e, Online Resource 
4f), again indicating that Pur-alpha modulates the p62 protein 
level.
To assess whether overexpression of p62 had a protective 
effect on RNA toxicity, p62 RNA was co-injected with sense 
repeat RNA in zebrafish oocytes. Indeed, overexpression of 
p62 almost completely prevented repeat RNA toxicity (Fig. 7f, 
g). Interestingly and similar to Pur-alpha, overexpression of 
p62 did not affect the toxicity induced by GR (Fig. 7h, i), again 
highlighting the different underlying mechanisms of RNA 
versus DPR toxicity. Altogether these data suggest that the 
protective effect of Pur-alpha is mediated by its modulating 
effect on p62.
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Discussion
We generated a novel C9 ALS/FTD repeat-associated model 
in zebrafish to investigate the mechanism through which this 
repeat causes toxicity. We found that injection of sense ~ 70 
GGG GCC repeat RNA was dose dependently toxic to 
motor axons in this model. It induced a phenotype similar 
to that of overexpression of mutant SOD1 and TDP-43 as 
Fig. 4  Supporting evidence for RNA toxicity. a, b Axonal length 
(a) and aberrant axonal branching (b) upon injection with a low 
dose (0.211  µM) of a single DPR-encoding mRNA, a combination 
of four DPRs at the same dose or these four DPRs together with a 
low dose (0.211  µM) of  ~  70S repeat RNA (n  =  6 experiments). a 
Data represent mean  ±  95% CI one-way ANOVA, F(6826)  =  6.5, 
*p  <  0.05. b Data represent mean  ±  95% CI logistic regression (z 
values compared to GFP 1.688, 1.543, 0.454, − 0.014, 2.166, 2.005), 
*p < 0.05. c, d Axonal length (c) and aberrant axonal branching (d) 
upon injection with a high dose (0.844 µM) of GA- or GP-encoding 
mRNA with a  low dose (0.211  µM) of  ~  90S repeat RNA (n  =  4 
experiments). c Data represent mean  ±  95% CI one-way ANOVA, 
F(5, 459) = 2.55. d Data represent mean ± 95% CI logistic regres-
sion (z value of GA + GFP vs GA + 91S: 0, z value of GP + GFP 
vs GP  +  91S −  0.467). e, f Axonal length (e) and aberrant axonal 
branching (f) upon injection with high dose (0.844  µM) of GA- or 
GP-encoding mRNA with low dose (0.211  µM) of  ~  70AS repeat 
RNA (n = 4 experiments). e Data represent mean ± 95% CI one-way 
ANOVA, F(5, 464) = 1.099. f Data represent mean ± 95% CI logistic 
regression (z value of GA + GFP vs GA + 70AS: 0.388, z value of 
GP + GFP vs GP + 70AS − 0.939). g, h Axonal length (g) and aber-
rant axonal branching (h) upon injection with stop codon-interrupted 
sense (white bars) and antisense (red bars) repeat RNA at equimolar 
dose (0.844 µM), n = 7 experiments. g Data represent mean ± 95% 
CI one-way ANOVA, F(6,1659) = 40.94, *p < 0.05, ***p < 0.001, 
****p  <  0.0001. h Data represent mean  ±  95% CI logistic regres-
sion (z values compared to GFP 8.507, 1.287, 4.823, 4.573, − 1.259, 
0.113; z value of 70S vs 70RO − 5.487; z value of 70AS vs 70RO AS 
− 2.843), **p < 0.01, ***p < 0.001, ****p < 0.0001
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we have shown before [29, 31]. When testing a range of 
repeat lengths, we found the threshold of sense toxicity to 
be between 10 and ~ 35 repeats. Interestingly, above this 
threshold the phenotype was not repeat length dependent, 
as the ~ 35, ~ 70 and the ~ 90 sense repeat RNA induced a 
similar phenotype. Both findings are in line with a presumed 
threshold of pathogenicity around 30 repeats in C9 ALS/
FTD patients on the one hand and the lack of a clear cor-
relation between repeat length and phenotype on the other 
hand [26, 48]. However, no firm conclusions can be drawn 
Fig. 5  Pur-alpha prevents repeat induced axonopathy in the zebrafish. 
a, b Dose-dependent effect of injection of Pur-alpha mRNA (0.072–
0.143–0.287–0.573 µM) on ~ 70S (0.844 µM) axonal toxicity, statis-
tics are compared to the second condition, i.e., 70S (n  =  3 experi-
ments). a Data represent mean  ±  95% CI one-way ANOVA, F(6, 
310)  =  21.56, ****p  <  0.0001. b Data represent mean  ±  95% CI 
logistic regression (z values −  3.516, −  0.393, −  1.272, −  1.594, 
− 2.007, − 2.909), *p < 0.05, **p < 0.01, ***p < 0.001. c, d Effect 
of hnRNPA1 (‘A1’; 0.108  µM) and hnRNPH1 (‘H1’; 0.030  µM) 
on  ~  90S (0.844  µM) axonal toxicity, statistics are compared to 
the second condition, i.e., 90S  +  GFP (n  =  8 experiments). c Data 
represent mean  ±  95% CI one-way ANOVA, F(3, 460)  =  29.63, 
****p < 0.0001. d Data represent mean ± 95% CI logistic regression 
(z values −  3.157, 0.393, −  0.624), **p  <  0.01. e, f Whole-mount 
staining (Hoechst) of 30  hpf zebrafish embryos injected with fluo-
rescently labeled  ~  90S repeat RNA together with GFP (e) or Pur-
alpha (f) Mrna, respectively. g Quantification of number of RNA foci 
per cell in conditions of panel e and f, n  =  8 embryos, data repre-
sent mean ± SEM, unpaired t test (t14 = 5.677), ****p < 0.0001. h, 
i Effect of Pur-alpha (0.573 µM) on PR and GR (0.844 µM) axonal 
toxicity (n = 6 experiments). h Data represent mean ± 95% CI one-
way ANOVA, F(4, 444)  =  18.49, (PR  +  GFP vs PR  +  Pur-alpha: 
p = 0.7575; GR + GFP vs GR + Pur-alpha: p = 0.9235). i Data rep-
resent mean ± 95% CI logistic regression (PR + GFP vs PR + Pur-
alpha: z value = − 1.340, p = 0.18; GR + GFP vs GR + Pur-alpha: z 
value = − 1.123, p = 0.261)
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since repeat lengths in the range of hundreds to thousands, 
as is mostly the case in C9orf72 ALS patients, could not be 
investigated in this model due to the inherent instability of 
these constructs.
We also report, for the first time, direct in vivo toxicity of 
the antisense repeat RNA. In our model, the threshold for the 
antisense repeat to induce toxicity was higher as compared 
to that of the sense toxicity; it was between ~ 35 and ~ 70 
repeats, while the latter is between 10 and ~ 35 repeats.
Using this model, we investigated whether expanded 
GGG GCC repeat RNA can be directly toxic, independent 
of the generation of DPRs. We first tested DPR toxicity 
by generating DPRs from codon-optimized constructs. 
These constructs generate DPRs without the need for 
repeat RNA using the freedom afforded by the wobble 
base principle. When testing all DPRs in our zebrafish 
model, GR and PR induced motor axon toxicity, whereas 
PA, GA and GP induced no obvious toxicity. It is unlikely 
Fig. 6  The protective effect of Pur-alpha is mediated by its G-rich 
and PUR2 domain. a Pur-alpha protein and the five deletion mutants; 
numbers indicate amino acid position in N- to C-terminal order. b 
Confirmation of in  vivo translation of mRNA encoding the differ-
ent Pur-alpha mutants in 30  hpf zebrafish embryos by Western blot 
(FLAG antibody), n  =  2 biological replicates. c, d Binding affin-
ity of the different Pur-alpha deletion mutants to  ~  70S RNA as 
assessed by RNA pull-down (‘RNA PD’) followed by Western blot-
ting using FLAG antibody, n  =  4 biological replicates (c—upper 
panel). Input; immunoprecipitation (FLAG antibody) of HEK cells 
transfected with the different Pur-alpha deletion mutants followed 
by Western blot using FLAG antibody (c–lower panel). d Quan-
tification of RNA pull-down, data are normalized to input. Data 
represent mean  ±  SEM, one-way ANOVA, F(5, 17)  =  3.471. e, f 
Effect of the different Pur-alpha deletion mutants at equimolar dose 
(0.573 µM) on ~ 90S (0.844 µM) axonal toxicity (n = 5 experiments), 
statistics are compared to the second condition (90S + GFP). e Data 
represent mean  ±  95% CI one-way ANOVA, F(7, 827)  =  23.37, 
****p  <  0.0001. f Data represent mean  ±  95% CI logistic regres-
sion (z values − 3.350, − 2.634, − 0.559, − 2.506, − 0.816, − 1.439, 
− 2.584), *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 7  p62 is necessary and sufficient for the protective effect of 
Pur-alpha on RNA toxicity. a Quantification of Danio rerio p62 
protein levels in 30 hpf zebrafish embryos upon injection of  ~  70S 
(0.844 µM) repeat RNA as assessed by Western blot. Data represent 
mean ± SEM, statistics are compared to GFP condition, n = 8 experi-
ments, ratio paired t test (t7  =  0.2229). b Quantification of Danio 
rerio p62 protein levels in 30  hpf zebrafish embryos upon injection 
of PURA, ΔG or ΔPUR2 mRNA at equimolar dose (0.573  µM) as 
assessed by Western blot. Data represent mean ± SEM, statistics are 
compared to GFP condition, n = 7–11 experiments, ratio paired t test 
(PURA t10 = 3.316, ΔG t6 = 2.64, ΔPUR2 t6 = 3.142), *p < 0.05, 
**p  <  0.01. c, d Effect of morpholino (0.30  mM)-mediated p62 
knockdown on the protective effect of Pur-alpha on RNA toxic-
ity (n  =  11 experiments; p62 MO p62 morpholino, co MO control 
morpholino). c Data represent mean  ±  95% CI one-way ANOVA, 
F(4, 789)  =  28.24, ***p  <  0.001, ****p  <  0.0001. d Data repre-
sent mean ± 95% CI logistic regression (z value of condition 2 vs 3: 
− 2.363; z value of condition 4 vs 5: 3.027), *p < 0.05, **p < 0.01. 
e Quantification of Danio rerio pura and p62 protein levels in 30 hpf 
zebrafish embryos upon morpholino (0.05  mM)-mediated pura 
knockdown (purMO pura morpholino). Data represent mean ± SEM, 
statistics are compared to control morpholino condition, n  =  10 
experiments, ratio paired t test (pura t9  =  3.717, p62 t9  =  3.532), 
**p  <  0.01. f, g Effect of injection of p62 mRNA (0.153  µM) 
on  ~  70S (0.844  µM) axonal toxicity (n  =  6 experiments). f Data 
represent mean  ±  95% CI one-way ANOVA, F(2, 258)  =  18.46, 
****p  <  0.0001. g Data represent mean  ±  95% CI logistic regres-
sion (z values compared to GFP 2.613, 0.596; z value of 70S + GFP 
vs 70S  +  p62 −  2.165), *p  <  0.05, **p  <  0.01. h, i Effect of p62 
(0.153 µM) on GR (0.844 µM) axonal toxicity (n = 7 experiments). h 
Data represent mean ± 95% CI one-way ANOVA, F(2, 309) = 6.546, 
*p  <  0.05, **p  <  0.01. i Data represent mean  ±  95% CI logis-
tic regression (z values compared to GFP 3.205, 2.120; z value of 
GR + GFP vs GR + p62 − 1.246), *p < 0.05, **p < 0.01
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that RNA toxicity contributes to the PR- and GR-induced 
axonopathy because of the absence of repeats in the RNA 
sequence. Furthermore, elimination of the ATG initiation 
codon abolished the toxic effect of the PR construct. The 
finding that mostly arginine-containing DPRs display neu-
rotoxicity in this in vivo model is in line with the findings 
in Drosophila [4, 33] and provides evidence for a potential 
role of these DPRs in C9 ALS/FTD pathology. Despite the 
observation of GA forming abundant aggregates, it failed 
to induce motor axon toxicity in our model. Hence, this 
in vivo model does not support the relationship between 
the aggregating aspect of GA and its toxicity as was sug-
gested by others [53].
Based on our findings from DPR-expressing fish, one 
could hypothesize that the neurotoxicity observed in repeat 
RNA injected fish is due to the formation of toxic arginine-
containing DPRs through RAN translation; GR in the sense 
direction and PR in the antisense direction. Our data provide 
several lines of evidence that suggest otherwise.
First, using DPR-specific antibodies we failed to show 
the formation of PR, GR and GP in zebrafish injected with 
either sense or antisense repeat RNA. It may be argued 
that the level of expression in the zebrafish is below the 
detection limit. However, we were able to detect PR expres-
sion even below the threshold for toxicity. Therefore, it is 
unlikely that their abundance is below the detection limit 
when injecting the toxic ~ 70 antisense RNA. It could be 
argued that a combination of DPRs mediates toxicity, while 
they each separately remain below the detection limit. We 
could, however, exclude such a synergistic toxicity, both at 
the DPR–DPR level and at the DPR–RNA level. Moreover, 
based on these findings, RAN translation might not occur in 
this early developmental stage of zebrafish, as was suggested 
by others [36], or only at a very low level as suggested by 
our immunoassay findings.
Second, both sense and antisense ‘RNA only’ constructs 
of a length of 70 and 108 repeats induced clear toxicity in 
our model. By inserting stop codons in all reading frames 
in both directions, RAN translation is completely ruled out 
with these constructs. Hence, toxicity arising from these 
RNAs is likely to be due to a direct effect of the repeat RNA 
itself. However, we did observe that the presence of inter-
ruptions slightly diminished the toxicity of the repeat con-
structs. This may be due to an alteration of the RNA–pro-
tein interaction affinities caused by the interruptions, which 
may compromise the toxic potential of these RNAs as was 
suggested by others [6]. Alternatively, this may indicate a 
residual effect of DPR toxicity arising from non-interrupted 
repeat RNA. However, as explained above, this is not sup-
ported by our data. Of note, while these ‘RNA only’ con-
structs display toxicity in zebrafish, they do not in Drosoph-
ila [33], suggesting a different sensitivity to RNA toxicity in 
zebrafish versus Drosophila models.
Third, we observed a differential effect of overexpressing 
Pur-alpha on the toxicity of the repeat RNA versus that of 
the DPRs. Pur-alpha reduced the toxicity of sense and anti-
sense repeat RNA, but had no effect on GR or PR toxicity. 
The finding that Pur-alpha also robustly abrogated the toxic-
ity of the interrupted repeat RNAs excludes the possibility 
that the protective effect of Pur-alpha relies on inhibition of 
RAN translation. This means that the toxicity of sense and 
antisense repeat RNA must, at least partially, rely on patho-
physiological mechanisms other than the toxicity observed 
in GR and PR, and is hence indirect evidence for the exist-
ence of RNA toxicity.
Next, we aimed to elucidate some aspects of the mecha-
nism of this RNA toxicity. Sequestration of several RNA 
binding proteins by abnormally long GGG GCC repeats has 
been suggested to be an important pathogenic factor in C9 
ALS/FTD, similar to what is thought to happen in myotonic 
dystrophy [45]. In this disease, the sequestration of the pro-
tein muscleblind by the CUG repeat may explain the pheno-
type. We studied three proteins (hnRNPA1, hnRNPH1 and 
Pur-alpha) which were shown to bind the ~ 70S repeat RNA. 
Pur-alpha has already been shown to be able to rescue the eye 
abnormalities in Drosophila expressing a GGG GCC repeat 
[51]. Concordantly, we observed in our zebrafish model that 
Pur-alpha overexpression protected against the RNA toxicity 
arising from both the sense and antisense strand, supporting 
the hypothesis of RNA-binding protein sequestration as a 
possible pathogenic mechanism. hnRNPA1 and hnRNPH1, 
despite being able to bind the sense RNA repeats, showed 
no clear rescuing effect, strengthening the specificity of the 
Pur-alpha findings in our model.
Since sense and antisense repeat RNA foci are a patholog-
ical hallmark of C9orf72 ALS, we investigated its presence 
in our zebrafish model. First, we found both toxic (~ 90 sense 
and ~ 70 antisense) and non-toxic (3 sense) repeat RNA to 
form RNA foci, suggesting that, at least in our model, there 
is no clear correlation between presence of RNA foci and 
toxicity. Second, both sense and antisense repeat RNA were 
found to be mainly localized to the cytoplasm, both diffusely 
as well as in RNA foci. While in C9orf72 patients most RNA 
foci have been found to be located in the nucleus, cytoplas-
mic RNA foci have also been found in postmortem tissue 
[11, 12, 34], as well as in patient-derived cell cultures [17]. 
These data suggest that RNA toxicity might be mediated 
by cytoplasmic repeat RNA, which might explain why no 
correlation between extent of nuclear RNA foci and neu-
rodegeneration has been found in postmortem tissue [15]. 
Third, we observed a decrease in RNA foci upon Pur-alpha 
overexpression while Pur-alpha did not colocalize with RNA 
foci. This suggests that Pur-alpha mainly interacts with solu-
ble repeat RNA, which, therefore, may be the main mediator 
of RNA toxicity rather than RNA foci are.
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To investigate the underlying mechanisms of RNA toxic-
ity, we further examined the protective effect of Pur-alpha. 
The 322-amino acid (AA)-containing protein Pur-alpha 
can roughly be divided into five functional domains [14]: 
an N-terminal glycine-rich domain (G-rich; AA7-53), two 
regions with high affinity for purine rich RNA/DNA (PUR1; 
AA59-123–PUR2; AA142-209), a region also with purine 
affinity but implicated in Pur-alpha dimerization (PUR3; 
AA218-278) and a C-terminal glutamine–glutamate-rich 
domain (EQ; AA282-322). We found that deleting the 
G-rich or PUR2 domain abolishes the effect. Interestingly, 
deleting these domains does not interfere with the binding of 
the mutant Pur-alpha protein to repeat RNA. This suggests 
that the protective effect does not only result from interfer-
ing with a sequestration process, e.g., through shielding of 
repeat RNA by exogenous Pur-alpha protein. Instead, Pur-
alpha must exert its protective effect also through specific 
functions of its G-rich and PUR2 domain; hence, investigat-
ing these functions might provide important insights into the 
mechanism of RNA toxicity.
We investigated this in our RNA toxicity zebrafish model. 
First, as opposed to findings in C9orf72 iPSC-derived neu-
rons [1, 13], we observed no increased levels of p62. How-
ever, p62 was upregulated by overexpression of Pur-alpha 
but not by the Pur-alpha deletion constructs lacking the 
G-rich or PUR2 domain. Thus, these two domains appear 
to be necessary for Pur-alpha to increase p62 expression and 
to be protective. Moreover, when p62 was knocked down, 
the protective effect of Pur-alpha was abolished. This sug-
gests that p62 upregulation is necessary for the protective 
effect of Pur-alpha. Second, overexpression of p62 almost 
completely prevented RNA toxicity in our zebrafish model. 
This suggests that the inductive effect on p62 is sufficient for 
Pur-alpha to have its protective effect. This beneficial effect 
of p62 is in line with the observation of loss-of-function 
mutations in SQSTM1 (the gene coding the p62 protein) 
as a cause of ALS [43]. Moreover, p62 was also able to 
reduce TDP43 aggregation [5]. Similarly, overexpression of 
p62 is beneficial in other neurodegenerative diseases [20, 
40]. Hence, these data suggest that the observed increase 
in p62 in some C9orf72 models probably represents an 
attempted beneficial compensatory upregulation by the cell. 
Altogether, these data, unexpectedly, relate RNA toxicity 
to autophagy. Interestingly, since the C9orf72 protein itself 
is involved in autophagy as well, these findings support a 
multiple-hit model of C9 ALS in which reduced autophagy 
by loss of C9orf72 function might exacerbate RNA toxicity 
[49].
Altogether, our findings show that expanded C9orf72 
hexanucleotide repeat-associated neurodegeneration arises, 
at least in part, from RNA toxicity independent of DPRs. 
This has important translational implications, especially for 
the design of therapeutic approaches. Assuming that both 
RNA and DPR toxicity play a role in the disease mechanism, 
approaches targeting both modalities, such as antisense oli-
gonucleotides or small molecules, have the highest thera-
peutic potential as opposed to approaches targeting DPR 
toxicity only.
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